Binds Antigen Characterized By Name Or Molecular Weight (e.g., Cea, Nca, Cc Glycoprotein, Melanoma Gp 150 Antigen, Etc.) Patents (Class 530/388.85)
-
Publication number: 20020136716Abstract: The invention relates generally to compositions useful in altering the migration and/or proliferative activity of cells and to methods of using them. Reagents that can regulate cell migration and reorganization are useful in managing diseases in which cell migration and tissue remodeling play a role, including inhibiting vascular stenosis and restenosis that can result from endothelial injury. Migration-altering compositions include the proteins clusterin and gp38k and fragments thereof which retain the migration-altering activity, peptides derived from the proteins which possess the migration-altering activity, polyclonal, monoclonal and recombinant humanized antibodies directed against the proteins and fragments thereof and anti-sense oligonucleotides capable of binding clusterin and gp38k mRNAs.Type: ApplicationFiled: December 10, 1999Publication date: September 26, 2002Inventor: ALBERT J. T. MILLIS
-
Patent number: 6455677Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: GrantFiled: April 29, 1999Date of Patent: September 24, 2002Assignee: Boehringer Ingelheim International GmbHInventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Lèger, Jose William Saldanha
-
Patent number: 6451995Abstract: Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-GD2 antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target GD2-producing tumor cells.Type: GrantFiled: September 18, 1998Date of Patent: September 17, 2002Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Nai-Kong V. Cheung, Steven M. Larson, Hong-Fen Guo, Ken Rivlin, Michel Sadelain
-
Patent number: 6451979Abstract: Antibodies that will specifically bind to NBS-1 are described. It is also shown that NBS-1 will interact with p53 responsive elements in a p53 promoter. Thus, NBS-1 can be used in subjects having a p53-dependent tumor to inhibit growth of that tumor.Type: GrantFiled: May 12, 1998Date of Patent: September 17, 2002Assignee: Dana-Farber Cancer Institute, Inc.Inventors: William Kaelin, Christine Jost
-
Patent number: 6451981Abstract: Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding LAM-1, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-toxic pharmaceutical carrier substance. Additionally, antibodies that bind human LAM-1 and inhibit cellular adhesion, migration or infiltration into tissues are described.Type: GrantFiled: June 2, 1995Date of Patent: September 17, 2002Assignee: Dana-Farber Cancer InstituteInventor: Thomas F. Tedder
-
Publication number: 20020127595Abstract: An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.Type: ApplicationFiled: October 16, 1998Publication date: September 12, 2002Inventors: MICHAEL S. O'REILLY, M. JUDAH FOLKMAN
-
Patent number: 6448379Abstract: Inhibitors, including antibodies, of IL8 binding to its receptors, that interact with the amino-terminal extracellular domain of the IL8 receptor and which compete with IL8 for receptor-binding, are disclosed. The inhibitors are useful modulators of IL8 receptor-mediated biological activity.Type: GrantFiled: September 14, 1993Date of Patent: September 10, 2002Assignee: Chiron CorporationInventors: Patricia Tekamp-Olson, Guy Mullenbach, Mary Ellen Wernette-Hammond
-
Patent number: 6447776Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas.Type: GrantFiled: July 23, 1997Date of Patent: September 10, 2002Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Heinz Höfler, Karl-Friedrich Becker, Elisabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
-
Patent number: 6444207Abstract: Disclosed is a method for treating a gastrointestinal tumor by administering a murine antibody which specifically binds an epitope of 17-1A antigen.Type: GrantFiled: September 16, 1994Date of Patent: September 3, 2002Assignee: Centocor, Inc.Inventors: Hubert J. P. Schoemaker, Richard A. Carrano
-
Patent number: 6441143Abstract: Anti-p185HER-2/neu antibodies which are useful in the detection of HER-2/neu oncogene overexpression in biological samples are described. The antibodies are accurate and reliable in immunocytochemical or immunohistochemical assays of cell and tissue samples. Also described are methods for detecting HER-2/neu oncogene expression in a biological sample using the antibodies of the invention and a diagnostic kit comprising the antibodies. The reagents provide an accurate means of identifying certain cancer patients who have the greatest probability of relapse and/or the least likelihood of survival.Type: GrantFiled: March 23, 1998Date of Patent: August 27, 2002Assignee: Amgen INCInventor: Raymond A. Koski
-
Patent number: 6441142Abstract: Peanuts are a common cause of food hypersensitivity reactions. The sera of 10 patients who had atopic dermatitis and a positive double-blind placebo-controlled food challenge to peanut were used to investigate the major allergens of peanut. Crude Florunner extracts were fractionated by anion-exchange chromatography using a step gradient (limit buffer, 0.05M BisTris/1.5M NaCl). One hundred microliters of each 2.0 ml fraction was dot-blotted onto nitrocellulose paper and IgE-binding activity assessed using the serum pool to select allergen-containing fractions. A protein peak (OD 280) which eluted at 10% NaCl and demonstrated intense IgE-binding was further analyzed by two-dimensional SDS-PAGE/immunoblot analysis. The majority of this fraction is a protein which has a molecular weight of 17 kD and a pI of 5.2. Sequencing data from the N-terminus revealed the following initial 9 amino acids: (*)-Q-Q-(*)-E-L-Q-D-L.Type: GrantFiled: June 18, 1999Date of Patent: August 27, 2002Assignee: University of ArkansasInventors: A. Wesley Burks, Jr., Ricki M. Helm
-
Publication number: 20020114804Abstract: An agent capable of inhibiting signalling mediated by a &bgr;1 integrin cell surface receptor of leukocyte cells will treat a bacterial infection associated with a surface of a foreign body over and around which fibrin has been deposited, or a malignant tumor over and around which tenascin has been deposited. In addition, coating a foreign body with a fibrinolytic agent will prevent chronic bacterial infection associated with the surface of the foreign body. Furthermore, an agent capable of stimulating signalling mediated by a &bgr;1 integrin cell surface receptor of leukocyte cells will treat chronic inflammation.Type: ApplicationFiled: October 22, 1998Publication date: August 22, 2002Inventors: JOHN LOIKE, SAMUEL C. SILVERSTEIN
-
Patent number: 6437098Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: GrantFiled: January 5, 1999Date of Patent: August 20, 2002Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6417337Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.Type: GrantFiled: February 18, 1998Date of Patent: July 9, 2002Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6417335Abstract: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.Type: GrantFiled: October 3, 2000Date of Patent: July 9, 2002Assignee: Genentech, Inc.Inventors: Carol D. Basey, Greg S. Blank
-
Publication number: 20020086444Abstract: The present invention relates, in general, to presenilin 2 proteolytic fragments. In particular, the present invention relates to a purified 20 kDa presenilin 2 C-terminal fragment (PS2-CTF); purified nucleic acid molecules coding for the 20 kDa PS2-CTF protein; cells containing the nucleic acid molecules; non-human organisms containing the nucleic acid molecule; antibodies having specific binding affinity to the 20 kDa PS2-CTF; hybridomas containing the antibodies; methods of detecting 20 kDa PS2-CTF in a sample; diagnostic kits; methods for screening compounds that inhibit proteolytic processing of presenilin 2 in a cell, isolated compounds that inhibit proteolytic processing of presenilin 2 in a cell, and a method of inhibiting apoptotic cell death by preventing proteolytic cleavage of presenilin 2 at a cleavage site which generates a 20 kDa C-terminal fragment.Type: ApplicationFiled: April 24, 1998Publication date: July 4, 2002Inventors: RUDOLPH E. TANZI, TAE-WAN KIM
-
Patent number: 6410690Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.Type: GrantFiled: June 7, 1995Date of Patent: June 25, 2002Assignee: Medarex, Inc.Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
-
Patent number: 6399061Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.Type: GrantFiled: June 7, 1995Date of Patent: June 4, 2002Assignee: IDEC Pharmaceutical CorporationInventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 6399054Abstract: A method for the production of activated tumor-specific T cells by co-cultivating, ex vivo, tumor cells from a patient with T cells from that patient, comprising the steps of: i) incubating the tumor cells with a first fusion protein obtained from a B7 protein and one partner of a biological binding pair and a second fusion protein obtained from an antibody against a cell surface antigen and the other partner of the biological binding pair, ii) inhibiting the proliferation of the tumor cells prior to or after that incubation; iii) co-cultivating the tumor cells with the T cells to be activated, until activation of the T cells is attained; iv) separating the activated T cells from the tumor cells, is highly efficient and can be carried out in a simple manner.Type: GrantFiled: September 29, 1998Date of Patent: June 4, 2002Assignee: Science Park RAF S.p.A.Inventors: Giulia Casorati, Paolo Dellabona
-
Publication number: 20020065398Abstract: New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin.Type: ApplicationFiled: December 21, 1998Publication date: May 30, 2002Inventors: CRISTINA M.M.A. DEL RIO, ROLANDO PEREZ RODRIGUEZ, ERNESTO MORENO FRIAS
-
Patent number: 6395272Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.Type: GrantFiled: June 22, 1998Date of Patent: May 28, 2002Assignee: Mederex, Inc.Inventors: Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram
-
Patent number: 6391302Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: August 7, 2000Date of Patent: May 21, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Publication number: 20020058028Abstract: A method is disclosed where one or more biological stains are applied to living tissue displaying, or suspected of having cells, or parts of the tissue which are diseased, metaplasic, or otherwise abnormal, including but not limited to lesions which may be thought pre-cancerous or cancerous. The stained tissue is then analyzed, in situ, by reflectance spectroscopy, the results of which are then compared to a digital library of reflectance spectrums of such tissue that have been previously diagnosed by conventional histochemical techniques. The method is further disclosed as a means to monitor the progress of photodynamic therapy using the same biological stains as specific photosensitizers.Type: ApplicationFiled: May 5, 1999Publication date: May 16, 2002Inventors: MARK K. MALMROS, WILLIAM S. COLLINS, PIER J. CIPRIANI
-
Patent number: 6387698Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.Type: GrantFiled: August 18, 2000Date of Patent: May 14, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
-
Patent number: 6387371Abstract: A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.Type: GrantFiled: June 25, 1999Date of Patent: May 14, 2002Assignee: Genentech, Inc.Inventors: Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
-
Patent number: 6383759Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.Type: GrantFiled: January 15, 1999Date of Patent: May 7, 2002Assignee: Gerald P. Murphy Cancer FoundationInventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, Robert J. Barren, III
-
Publication number: 20020052480Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: ApplicationFiled: April 29, 1999Publication date: May 2, 2002Inventors: JOHN EDWARD PARK, PILAR GARIN-CHESA, UWE BAMBERGER, WOLFGANG J. RETTIG, OLIVIER LEGER, JOSE WILLIAM SALDANHA
-
Publication number: 20020052479Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.Type: ApplicationFiled: February 18, 1998Publication date: May 2, 2002Inventors: KERR W.H. ANDERSON, PHILIP TEMPEST, FRANK J CARR, WILLIAM J HARRIS, KATHRYN ARMOUR
-
Patent number: 6379668Abstract: A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.Type: GrantFiled: June 17, 1999Date of Patent: April 30, 2002Assignees: Research Corporation Technologies, Inc., Alimmune, LLCInventors: Andrew I. Lazarovits, Sibrand Poppema
-
Patent number: 6376654Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies and binding fragments thereto capable of being used for therapeutic, diagnostic, and cell purification purposes.Type: GrantFiled: August 13, 1999Date of Patent: April 23, 2002Assignee: Molecular Discoveries, LLCInventor: Cohava Gelber
-
Patent number: 6376653Abstract: Tie2 receptor antagonist antibodies, their use in inhibiting angiogenesis and other uses are disclosed.Type: GrantFiled: September 27, 1999Date of Patent: April 23, 2002Assignees: SmithKline Beecham plc, SmithKline Beecham CorporationInventors: Stephen D. Holmes, Connie L. Erickson-Miller, James D. Winkler
-
Publication number: 20020045196Abstract: Methods for isolating trophoblast cells from pregnant women are provided. A central maternal blood sample is obtained, typically from the uterine wall of a pregnant woman. The trophoblast cells are isolated from the central maternal blood sample.Type: ApplicationFiled: May 12, 2000Publication date: April 18, 2002Inventors: Walt Mahoney, Paula Schueler, Douglas Yamanishi
-
Patent number: 6372441Abstract: The invention relates to a method for diagnosing and treating Hodgkin's lymphomas (lymphogranulomatosis) which is based on the expression of the variant exon v10 of the CD44 gene as a molecular marker or target. There is a significant correlation between v10 expression and the stage and prognosis of the disease. In a preferred embodiment, v10-specific antibody molecules are used to measure the expression of the exon in samples. In another preferred embodiment, radiolabelled v10-specific antibodies are used to treat Hodgkin's lymphomas.Type: GrantFiled: December 21, 1999Date of Patent: April 16, 2002Assignees: Forschungszentrum Karlsruhe GmbH, Boehringer Ingelheim International GmbHInventors: Karl-Heinz Heider, Kurt Zatloukal, Christine Beham-Schmid
-
Publication number: 20020037288Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.Type: ApplicationFiled: August 11, 1999Publication date: March 28, 2002Inventors: YASUO KOISHIHARA, YASUSHI YOSHIMURA
-
Publication number: 20020031515Abstract: Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.Type: ApplicationFiled: May 14, 2001Publication date: March 14, 2002Inventors: Michael A. Caligiuri, Neal J. Meropol, Richard L. Schilsky
-
Patent number: 6355444Abstract: Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.Type: GrantFiled: June 10, 1997Date of Patent: March 12, 2002Assignee: Viventia Biotech Inc.Inventors: Mark C. Glassy, Helena R. Chang, Keiji Koda
-
Publication number: 20020026036Abstract: A process for the production of humanized chimera antibody, wherein the chimera antibody is produced easily without changing any of the amino acids of its mouse antibody variable region, which comprises the steps of: (1) constructing a cassette vector by inserting a cDNA coding for a heavy chain constant region of human antibody into an expression vector for animal cell use and establishing a cloning site in the upstream region of the heavy chain constant region of said cassette vector for inserting a cDNA which encodes a heavy chain variable region of nonhuman animal antibody; (2) digesting a cDNA coding for the heavy chain variable region of nonhuman animal antibody with restriction enzymes; (3) inserting said cDNA coding for the heavy chain variable region of nonhuman animal antibody into the cassette vector, using a synthetic DNA which comprises a base sequence corresponding to the 5′-end side of said heavy chain constant region of human antibody and a base sequence corresponding to the 3′-endType: ApplicationFiled: January 19, 2001Publication date: February 28, 2002Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6350861Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: May 23, 1997Date of Patent: February 26, 2002Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Patent number: 6348581Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: February 18, 1998Date of Patent: February 19, 2002Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6346249Abstract: The invention is directed to methods of reducing the effects of cancer in a subject by administering to said subject a pharmaceutically effective amount of an anti-cancer agent conjugated to an inmmunoglobulin product which comprises one or more novel complementarity determining region and framework regions.Type: GrantFiled: April 4, 2000Date of Patent: February 12, 2002Assignees: Ludwig Institute for Cancer Research, The Scripps Research InstituteInventors: Carlos F. Barbas, III, Christoph Rader, Gerd Ritter, Sydney Welt, Lloyd J. Old
-
Publication number: 20020016446Abstract: A recombinant vector for the expression and secretion of antibodies in single molecule form (scFv) in B.subtilis, where said vector comprises the promoter of the gene for neutral protease, a new secretion sequence (I) and a DNA sequence coding for an antibody scFv of interest, a strain of B.subtilis transformed with said recombinant vector, and a procedure for the exocellular production of scFv antibodies by means of a culture of said strain of B.subtilis are described. The recombinant vector allows the expression of scFv in a completely soluble form and its secretion in high yields.Type: ApplicationFiled: April 23, 1997Publication date: February 7, 2002Inventors: GUIDO GRANDI, FRANCESCA DE FERRA, CLAUDIO TOSI, ORNELLA TORTORA, ANNA CUZZONI
-
Patent number: 6342587Abstract: The invention is directed to novel CDRs and immunoglobulin products that bind to A33 antigens and methods for their use. The invention also involves a method for making humanized antibodies, using a rabbit as a host animal, and phage display library methodologies, and the antibodies themselves. The methodology is useful, for example, in generating humanized antibodies against molecules associated with cancer, such as A33, which is associated with colon cancer.Type: GrantFiled: October 22, 1999Date of Patent: January 29, 2002Assignees: Ludwig Institute for Cancer Research, The Scripps Research InstituteInventors: Carlos F. Barbas, III, Christoph Rader, Gerd Ritter, Sydney Welt, Lloyd J. Old
-
Publication number: 20020010321Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.Type: ApplicationFiled: December 29, 2000Publication date: January 24, 2002Inventors: Yao-tseng Chen, Matthew Scanlan, Ali O. Gure, Lloyd J. Old, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Elisabeth Stockert, Elke Jager, Knuth Alexander
-
Patent number: 6339142Abstract: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.Type: GrantFiled: October 3, 2000Date of Patent: January 15, 2002Assignee: Genentech, Inc.Inventors: Carol D. Basey, Greg S. Blank
-
Publication number: 20020001817Abstract: Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of protease resistant disease related protein in a sample and by subtracting that amount from the total amount of disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of pathogenic protein in a sample.Type: ApplicationFiled: July 9, 2001Publication date: January 3, 2002Inventors: Stanley B. Prusiner, Jiri G. Safar, Fred E. Cohen
-
Patent number: 6335014Abstract: A cancer metastasis inhibitor which comprises as an active ingredient an anti-tenascin monoclonal antibody which neutralizes the physiological functions of a tenascin by binding to the FGF-like domain and other domains of the tenascin and prevents the metastasis of cancer to other organs such as the lungs.Type: GrantFiled: June 17, 1998Date of Patent: January 1, 2002Assignees: The Institute of Physical and Chemical ResearchInventor: Moriaki Kusakabe
-
Patent number: 6335428Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 1A2 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 1A2 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 1A2, and in methods of measuring p450 1A2 levels in individuals relative to p450 1A2 levels in a control population.Type: GrantFiled: April 8, 1999Date of Patent: January 1, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Harry V. Gelboin, Frank J. Gonzalez, Tian J. Yang
-
Patent number: 6331286Abstract: Methods of treating and imaging diseased tissue having the steps of administering a radiosensitizer agent proximate to or into the diseased tissue; and treating the diseased tissue with x-rays or other ionizing radiation so as to activate the radiosensitizer agent in the diseased tissue. Preferably, the radiosensitizer agent is a halogenated xanthene.Type: GrantFiled: December 21, 1998Date of Patent: December 18, 2001Assignee: Photogen, Inc.Inventors: H. Craig Dees, Timothy Scott, John T. Smolik, Eric A. Wachter
-
Patent number: 6326472Abstract: Nucleic acids encoding mammalian, e.g., human receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: October 14, 1998Date of Patent: December 4, 2001Assignee: Schering CorporationInventors: Jacqueline C. Timans, Johannes Eduard Maria Antonius Debets, Theodore R. Sana, J. Fernando Bazan, Robert A. Kastelein
-
Patent number: RE37596Abstract: The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of neuroblastoma and other tumors of neuroectodermal origin, to hybridoma cell lines for the preparation thereof, and to the antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic, aid, active substance or active substance carrier.Type: GrantFiled: June 16, 1999Date of Patent: March 19, 2002Assignee: Dade Behring Marburg GmbHInventors: Klaus Bosslet, Bernhard Auerbach, Helmut Peters